Select Page

References – Neural Balance for Better Sleep

  1. Kripke, D. (2018). Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Research, 5, p.918.
  2. Kok, V., Horng, J., Hung, G., Xu, J., Hung, T., Chen, Y. and Chen, C. (2016). Risk of Autoimmune Disease in Adults with Chronic Insomnia Requiring Sleep-Inducing Pills: A Population-Based Longitudinal Study. Journal of General Internal Medicine, 31(9), pp.1019-1026.
  3. Petrov, M., Howard, V., Kleindorfer, D., Grandner, M., Molano, J. and Howard, G. (2014). Over-the-counter and Prescription Sleep Medication and Incident Stroke: The REasons for Geographic And Racial Differences in Stroke Study. Journal of Stroke and Cerebrovascular Diseases, 23(8), pp.2110-2116.
  4. Perkovic-Vukcevic, N., Vukovic-Ercegovic, G., Segrt, Z., Djordjevic, S. and Jovic-Stosic, J. (2016). Benzodiazepine poisoning in elderly. Vojnosanitetski pregled, 73(3), pp.234-238.
  5. Komada, Y., Takaesu, Y., Matsui, K., Nakamura, M., Nishida, S., Kanno, M., Usui, A. and Inoue, Y. (2016). Comparison of clinical features between primary and drug-induced sleep-related eating disorder. Neuropsychiatric Disease and Treatment, p.1275.
  6. Tom, S., Wickwire, E., Park, Y. and Albrecht, J. (2016). Nonbenzodiazepine Sedative Hypnotics and Risk of Fall-Related Injury. Sleep, 39(5), pp.1009-1014.
  7. Kripke, D. (2015). Mortality Risk of Hypnotics: Strengths and Limits of Evidence. Drug Safety, 39(2), pp.93-107.
  8. Pacher, P. (2006). The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 58(3), pp.389-462.
  9. Bortolato, M., Campolongo, P., Mangieri, R., Scattoni, M., Frau, R., Trezza, V., La Rana, G., Russo, R., Calignano, A., Gessa, G., Cuomo, V. and Piomelli, D. (2006). Anxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404. Neuropsychopharmacology, 31(12), pp.2652-2659.
  10. Jawna-Zboińska, K., Blecharz-Klin, K., Joniec-Maciejak, I., Wawer, A., Pyrzanowska, J., Piechal, A., Mirowska-Guzel, D. and Widy-Tyszkiewicz, E. (2016). Passiflora incarnataL. Improves Spatial Memory, Reduces Stress, and Affects Neurotransmission in Rats. Phytotherapy Research, 30(5), pp.781-789.
  11. Ngan, A. and Conduit, R. (2011). A Double-blind, Placebo-controlled Investigation of the Effects of Passiflora incarnata (Passionflower) Herbal Tea on Subjective Sleep QualityPhytotherapy Research, 25(8), pp.1153-1159.
  12. Lolli, L., Sato, C., Romanini, C., Villas-Boas, L., Santos, C. and Oliveira, R. (2007). Possible involvement of GABAA-benzodiazepine receptor in the anxiolytic-like effect induced by Passiflora actinia extracts in mice. Journal of Ethnopharmacology, 111(2), pp.308-314.
  13. Krenn, L. (2002). Die Passionsblume (Passiflora incarnata L.) – ein bewahrtes pflanzliches Sedativum*. Wiener Medizinische Wochenschrift, 152(15-16), pp.404-406.
  14. Kaviani, N., Tavakoli, M., Tabanmahr, M. and Gavaei, R. (2013). The Efficacy of Passiflora Incarnata Linnaeus in Reducing Dental Anxiety in Patients Undergoing Periodontal Treatment. J Dent (Shiraz), 14(2), pp.68-72.
  15. Appel, K., Rose, T., Fiebich, B., Kammler, T., Hoffmann, C. and Weiss, G. (2010). Modulation of the γ-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytotherapy Research, 25(6), pp.838-843.